Pharmaceuticals company Roche said a strong Swiss franc weighed on its earnings last year and contributed to a 5 percent drop in net income, which fell short of analysts’ estimates.
The Basel-based maker of Avastin and other cancer treatments reported Thursday that net income declined to 9.06 billion Swiss francs ($8.92 billion), from 9.54 billion in 2014, though income was up 4 percent after accounting for currency fluctuations. According to FactSet, analysts expected net income at 10.57 billion francs.
CEO Severin Schwan hailed a “successful” year and pointed to progress in Roche Holdings AG’s product pipeline and “important clinical data” in areas including cancer, multiple sclerosis, immune and blood diseases.
Sales rose 5 percent to 48.1 billion francs, largely behind U.S. pharmaceutical sales and strong demand for immunodiagnostic products.
Source: Associated Press
Filed Under: Drug Discovery
